AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

IMUGENE LTD

0.315

0.000

Volume:604.64K

Turnover:191.02K

Market Cap:99.33M

PE:-1.00

High:0.325

Open:0.315

Low:0.310

Close:0.315

52wk High:1.598

52wk Low:0.245

Shares:315.33M

Float Shares:254.20M

Volume Ratio:0.75

T/O Rate:0.24%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.316

EPS(LYR):-0.316

ROE:-84.54%

ROA:-37.27%

PB:2.21

PE(LYR):-1.00

Loading ...

Overview Company News Filings

Imugene's Phase 1b Study Date Confirmed by FDA to Support Phase 3 Registrational Study, Shares Jump 6%

MT Newswires Live

Imugene's Azer-Cel Hits 82% Response Rate in Lymphoma Trial

MT Newswires Live

Imugene and JW Therapeutics Partner to Advance CAR-T and Oncolytic Virus Therapy for Solid Tumors

Imugene and Jw Therapeutics Announce a Collaboration to Advance Oncarlytics and Carteyva® Combination in Solid Tumours

THOMSON REUTERS

Imugene Partners With Chinese Biotechnology Company to Trial Combination Therapy in Refractory Solid Tumors; Shares Up 3%

MT Newswires Live

BRIEF-Imugene Signs Strategic Collaboration With JW Therapeutics

BUZZ-Australia's Imugene gains on alliance with JW Therapeutics for tumour treatment

Imugene Ltd - Collaboration to Advance Oncarlytics and Carteyva Combination in Solid Tumours

THOMSON REUTERS

Imugene Ltd-Strategic Collaboration With Jw Therapeutics

THOMSON REUTERS

oToBrite Unveils Advanced Vision-AI Solutions for Outdoor Robotics and Unmanned Vehicles at iREX 2025 Including the New GMSL™ Camera with indie CVP and Developer Kit for Jetson Platform

Imugene Shareholders Reject Spill Resolution After Second Strike at Annual General Meeting, Shares Fall 6%

MT Newswires Live

Supreme Court has a packed house for Trump tariffs case amid shutdown

Imugene to Issue 19.5 Million Shares, Pay $3 Million in Cash to Precision Biosciences as Milestone Payment Under Licensing Agreement

MT Newswires Live

A toy maker takes his case against Trump's tariffs to the Supreme Court

Imugene Reports 83% Overall Response Rate From CAR T-Naive Niche Indication Portion of B-Cell Lymphoma Drug Candidate Trial, Shares Up 7%

MT Newswires Live

Mouser Electronics New Product Insider: Over 16,000 New Parts Added in Third Quarter of 2025

Imugene Says Drug Candidate Trial in Blood Cancer Patients Achieves 81% Overall Response Rate; Shares Rise 8%

MT Newswires Live

BRIEF-Imugene Posts FY Net Loss Attributable A$69 Million

Imugene Ltd - FY Net Loss Attributable a$69 Mln

THOMSON REUTERS

Imugene Ltd-Update - Proposed Issue of Securities - Imu

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/IMU.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IMU.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"IMU.AU\",,,,,undefined,":{"symbol":"IMU.AU","market":"AU","secType":"STK","nameCN":"IMUGENE LTD","latestPrice":0.315,"timestamp":1765861920000,"preClose":0.315,"halted":0,"volume":604640,"delay":0,"nameEN":"IMUGENE LTD","floatShares":254199099,"shares":315326785,"eps":-0.315594,"marketStatus":"Closed","change":0,"latestTime":"12-16 16:12:00 AEDT","open":0.315,"high":0.325,"low":0.31,"amount":191017,"amplitude":0.047619,"askPrice":0.32,"askSize":94274,"bidPrice":0.31,"bidSize":200847,"shortable":3,"etf":0,"ttmEps":-0.315594,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1765926000000},"marketStatusCode":5,"adr":0,"exchange":"ASX","adjPreClose":0.315,"openAndCloseTimeList":[[1765839600000,1765861200000]],"volumeRatio":0.749169,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"IMU.AU\",,,,,undefined,":{"symbol":"IMU.AU","floatShares":254199099,"roa":"-37.27%","roe":"-84.54%","lyrEps":-0.315594,"volumeRatio":0.749169,"shares":315326785,"dividePrice":0,"high":0.325,"amplitude":0.047619,"preClose":0.315,"low":0.31,"week52Low":0.245,"pbRate":"2.21","psRate":"22.59","week52High":1.598,"institutionHeld":0,"latestPrice":0.315,"committee":0.361116,"eps":-0.315594,"divideRate":0,"volume":604640,"delay":0,"ttmEps":-0.315594,"open":0.315,"prevYearClose":1.258,"prevWeekClose":0.32,"prevMonthClose":0.345,"prevQuarterClose":0.305,"fiveDayClose":0.345,"twentyDayClose":0.3,"sixtyDayClose":0.29},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IMU.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2025-07-02","symbol":"IMU.AU","type":"split","dateTimestamp":1751378400000,"forFactor":34,"toFactor":1,"ratio":34}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IMU.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IMU.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2589438379","title":"Imugene's Phase 1b Study Date Confirmed by FDA to Support Phase 3 Registrational Study, Shares Jump 6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2589438379","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589438379?lang=en_us&edition=fundamental","pubTime":"2025-12-08 11:38","pubTimestamp":1765165122,"startTime":"0","endTime":"0","summary":"Imugene  said the US Food and Drug Administration  confirmed data from the current phase 1b study with azer-cel therapy candidate plus IL-2 dosing regimen, including lymphodepletion conditioning, along with the safety profile, supported advancing to phase three registrational study, according to a Monday Australian bourse filing.It received written minutes from the FDA following its recent Type C meeting. This included directional confirmation that its proposed regimen for the pivotal program, which includes augmented lymphodepletion followed by a flat 500 million cell dose of azer-cel with 14 days of subcutaneous low-dose IL-2, is appropriate.The regulator endorsed the firm's dual-end point strategy, with overall response rate and durability being used for accelerated approval, and progression-free survival being used for full approval. It also asked that the control arm include several investigator-choice therapies.The third line and later diffuse large B-cell lymphoma, including pat","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","IMU.AU","BK7067"],"gpt_icon":0},{"id":"2588174581","title":"Imugene's Azer-Cel Hits 82% Response Rate in Lymphoma Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2588174581","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588174581?lang=en_us&edition=fundamental","pubTime":"2025-12-01 13:00","pubTimestamp":1764565213,"startTime":"0","endTime":"0","summary":"Imugene  said that its phase 1b trial of azercabtagene zapreleucel  in patients with relapsed or refractory diffuse large B-cell lymphoma showed an 82% overall response rate, with most patients responding within one to three months, according to a Monday filing with the Australian bourse.The durability of responses is improving, particularly in patients treated with azer-cel alongside interleukin-2, per the filing.Azer-cel, an allogeneic \"off-the-shelf\" chimeric antigen receptor  T-cell therapy, aims to overcome the access, manufacturing, and timing limitations of autologous CAR T-cell treatments, the filing said.The phase 1b trial is continuing at 10 sites in the US, with up to six sites planned in Australia after the first Australian patient at Royal Prince Alfred Hospital achieved a complete response, the filing added.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7002","CAR","BK7508","CAR.AU","IMU.AU","BK4022","BK7503","BK4230","BK7067"],"gpt_icon":0},{"id":"2586208061","title":"Imugene and JW Therapeutics Partner to Advance CAR-T and Oncolytic Virus Therapy for Solid Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2586208061","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586208061?lang=en_us&edition=fundamental","pubTime":"2025-11-28 13:01","pubTimestamp":1764306071,"startTime":"0","endTime":"0","summary":"Imugene Limited has announced a strategic collaboration with JW Therapeutics to advance a novel combination therapy for refractory solid tumors. The partnership will evaluate Imugene's onCARlytics  oncolytic virus in combination with JW Therapeutics' Carteyva, an approved CD19-directed autologous CAR-T cell therapy. The initiative includes preclinical studies and a Phase 1 investigator-initiated trial in China, employing a \"mark and kill\" strategy where the oncolytic virus induces CD19 expression on tumor cells, making them targetable by CAR-T cells. The collaboration aims to generate impactful preclinical and clinical data to explore new treatment paradigms for solid tumors.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Imugene Limit","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251128:nNDL6XF6wh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1583","BK7508","IMU.AU","BK7067","BK1161","02126"],"gpt_icon":0},{"id":"2586208704","title":"Imugene and Jw Therapeutics Announce a Collaboration to Advance Oncarlytics and Carteyva® Combination in Solid Tumours","url":"https://stock-news.laohu8.com/highlight/detail?id=2586208704","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586208704?lang=en_us&edition=fundamental","pubTime":"2025-11-28 13:00","pubTimestamp":1764306025,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251128:nTUA38GFTS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","BK7508","IMU.AU"],"gpt_icon":0},{"id":"2586829060","title":"Imugene Partners With Chinese Biotechnology Company to Trial Combination Therapy in Refractory Solid Tumors; Shares Up 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2586829060","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586829060?lang=en_us&edition=fundamental","pubTime":"2025-11-27 10:37","pubTimestamp":1764211066,"startTime":"0","endTime":"0","summary":"Imugene  partnered with biotechnology company JW Therapeutics  to assess the combination therapy of the company's oncolytic virus CF33-CD19, onCARlytics, and JW's CD19 CAR-T cell therapy, Carteyva, in patients with advanced solid tumors, according to a Thursday filing with the Australian bourse.The collaboration involves preclinical studies, both in vitro and in vivo, leading to a first-phase investigator-initiated trial conducted in China, the filing said.Imugene shares rose 3% in afternoon trade on Thursday.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","IMU.AU","BK7508"],"gpt_icon":0},{"id":"2586973862","title":"BRIEF-Imugene Signs Strategic Collaboration With JW Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2586973862","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586973862?lang=en_us&edition=fundamental","pubTime":"2025-11-27 09:56","pubTimestamp":1764208593,"startTime":"0","endTime":"0","summary":"BRIEF-Imugene Signs Strategic Collaboration With JW TherapeuticsNov 27 (Reuters) - Imugene Ltd IMU.AX:STRATEGIC COLLABORATION WITH JW THERAPEUTICSCOLLABORATION TO ADVANCE ONCARLYTICS AND CARTEYVA COMBINATION IN SOLID TUMOURSFurther company coverage: IMU.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251127:nTUE6YR8Y7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMU.AU","BK7067","BK7508"],"gpt_icon":0},{"id":"2586946912","title":"BUZZ-Australia's Imugene gains on alliance with JW Therapeutics for tumour treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2586946912","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586946912?lang=en_us&edition=fundamental","pubTime":"2025-11-27 09:04","pubTimestamp":1764205483,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Imugene gains on alliance with JW Therapeutics for tumour treatment** Shares of Imugene IMU.AX rise as much as 6.2% to A$0.345, the highest since November 6** The biotechnology compan","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251127:nL4N3X302I:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02126","BK7067","IMU.AU","BK1574","BK7508","BK1161","BK1583"],"gpt_icon":0},{"id":"2586933752","title":"Imugene Ltd - Collaboration to Advance Oncarlytics and Carteyva Combination in Solid Tumours","url":"https://stock-news.laohu8.com/highlight/detail?id=2586933752","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586933752?lang=en_us&edition=fundamental","pubTime":"2025-11-27 06:08","pubTimestamp":1764194898,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251126:nTUE6YR8Y7:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMU.AU","BK7508","BK7067"],"gpt_icon":0},{"id":"2586293378","title":"Imugene Ltd-Strategic Collaboration With Jw Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2586293378","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586293378?lang=en_us&edition=fundamental","pubTime":"2025-11-27 06:08","pubTimestamp":1764194898,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251126:nTUE6YR8Y7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","IMU.AU","BK7508"],"gpt_icon":0},{"id":"2586476959","title":"oToBrite Unveils Advanced Vision-AI Solutions for Outdoor Robotics and Unmanned Vehicles at iREX 2025 Including the New GMSL™ Camera with indie CVP and Developer Kit for Jetson Platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2586476959","media":"prnewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586476959?lang=en_us&edition=fundamental","pubTime":"2025-11-25 21:35","pubTimestamp":1764077700,"startTime":"0","endTime":"0","summary":"HSINCHU, Nov. 25, 2025 /PRNewswire/ -- As a proven provider of complete Vision-AI solutions for the automotive and robotics markets,oToBrite will unveila portfolio of next-generation visual perception technologies at iREX 2025. The showcase features the automotive-grade GMSL2 camera series, the VIO  camera, the oToSLAM multi-camera Vision-AI positioning system, and the new GMSL Camera Jetson Developer Kit—demonstrating strong capabilities in automotive imaging, sensor fusion, and AI-driven perception for outdoor robotics, UGVs, humanoid robots, and next-generation smart mobility applications.oToBritewill introduce its developer kits designed specifically for the Jetson AGX Orin and Jetson Orin Nano. These solutions accelerate multi-camera vision development on Jetson platforms. The oToAdapter-GMSL-AGX-Orin supports up to eight GMSL2 cameras with 275 TOPS of AI performance, while the oToAdapter-GMSL-Orin-Nano supports up to four cameras with 67 TOPS—both offering plug-and-play integrati","market":"hk","thumbnail":"https://mma.prnewswire.com/media/2830717/irex.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2830717/irex.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/otobrite-unveils-advanced-vision-ai-solutions-for-outdoor-robotics-and-unmanned-vehicles-at-irex-2025-including-the-new-gmsl-camera-with-indie-cvp-and-developer-kit-for-jetson-platform-302625704.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999001069.SGD","BK6031","SG9999004360.SGD","BK6102","SG9999003461.SGD","BK4023","BK4528","BK6501","IMU.AU","SG9999003826.SGD","BK4551","A7RU.SI","BK7067","AI","BK4543","BK4588","SG9999002950.SGD","BK4585","BK4587","BK7508"],"gpt_icon":0},{"id":"2583532351","title":"Imugene Shareholders Reject Spill Resolution After Second Strike at Annual General Meeting, Shares Fall 6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2583532351","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583532351?lang=en_us&edition=fundamental","pubTime":"2025-11-13 12:59","pubTimestamp":1763009969,"startTime":"0","endTime":"0","summary":"Imugene  faced a second strike at its annual general meeting on Thursday after 30.33% of the votes cast at the poll opposed its remuneration report, according to a same-day Australian bourse filing.However, the board's spill meeting resolution was rejected, with 84.95% of the votes cast against it.Over 25% of a firm's shareholders are required to vote against its remuneration report to trigger the first strike. At the next year's annual general meeting, if over 25% of its shareholders again vote against the remuneration report, the company receives a strike, and its shareholders are required to immediately vote on whether to hold a spill meeting to replace the board.The firm's shares fell 6% in recent trading on Thursday.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","IMU.AU","BK7508"],"gpt_icon":0},{"id":"2581389700","title":"Supreme Court has a packed house for Trump tariffs case amid shutdown","url":"https://stock-news.laohu8.com/highlight/detail?id=2581389700","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581389700?lang=en_us&edition=fundamental","pubTime":"2025-11-06 05:46","pubTimestamp":1762379168,"startTime":"0","endTime":"0","summary":"Supreme Court has a packed house for Trump tariffs case amid shutdownTrump's treasury and commerce secretaries in attendanceUS government in the midst of a long-running shutdownJustices cast doubt on legality of Trump tariffsBy Blake Brittain","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"2a0adfca212c856d853f155a1bc6ef6d","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nL6N3WG1QY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","IMU.AU","BK7508"],"gpt_icon":0},{"id":"2580268018","title":"Imugene to Issue 19.5 Million Shares, Pay $3 Million in Cash to Precision Biosciences as Milestone Payment Under Licensing Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2580268018","media":"MT Newswires Live","labels":["shareholding","corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580268018?lang=en_us&edition=fundamental","pubTime":"2025-11-03 14:09","pubTimestamp":1762150155,"startTime":"0","endTime":"0","summary":"Imugene  said it will issue 19.5 million shares and pay $3 million in cash to Precision Biosciences as consideration for achieving the first milestone event under a license agreement between the two companies, according to a Monday Australian bourse filing.Imugene reached the milestone when exploring discussions with the US Food and Drug Administration regarding a potential pivotal trial for the azer-cel technology, which it in-licensed from Precision in 2023.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","BK7508","IMU.AU"],"gpt_icon":0},{"id":"2580425344","title":"A toy maker takes his case against Trump's tariffs to the Supreme Court","url":"https://stock-news.laohu8.com/highlight/detail?id=2580425344","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580425344?lang=en_us&edition=fundamental","pubTime":"2025-11-01 18:00","pubTimestamp":1761991200,"startTime":"0","endTime":"0","summary":"A toy maker takes his case against Trump's tariffs to the Supreme CourtSupreme Court to hear tariffs arguments on WednesdayTrump invoked emergency powers in imposing tariffsPlaintiffs accused Trump of","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251101:nL1N3W90NJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1525","BK1502","BK1601","BK4566","BK4585","HAS","BK1602","BK4588","BK7508","MAT","BK7067","BK1577","00178","BK4190","BK1224","IMU.AU"],"gpt_icon":0},{"id":"2579294245","title":"Imugene Reports 83% Overall Response Rate From CAR T-Naive Niche Indication Portion of B-Cell Lymphoma Drug Candidate Trial, Shares Up 7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579294245","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579294245?lang=en_us&edition=fundamental","pubTime":"2025-10-29 13:01","pubTimestamp":1761714101,"startTime":"0","endTime":"0","summary":"Imugene  said data from its phase 1b clinical trial evaluating the azer-cel drug candidate in patients with B-cell lymphoma showed an overall response rate of 83% in six evaluable heavily pretreated chimeric antigen receptor  T-nave patients in the CAR T-naive niche indication portion of the trial, according to a Monday Australian bourse filing.Three out of the six patients reported a complete response. A total of ten patients have been treated in the cohort thus far.The firm's shares rose 7% in recent trading on Wednesday.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IMU.AU","BK7508","BK7503","BK4230","CAR","BK4022","BK7067","CAR.AU","BK7002"],"gpt_icon":0},{"id":"2577445808","title":"Mouser Electronics New Product Insider: Over 16,000 New Parts Added in Third Quarter of 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2577445808","media":"prnewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577445808?lang=en_us&edition=fundamental","pubTime":"2025-10-21 15:30","pubTimestamp":1761031800,"startTime":"0","endTime":"0","summary":"SHANGHAI, Oct. 21, 2025 /PRNewswire/ --As an authorized global distributor,Mouser Electronics, Inc. is focused on the rapid introduction of new products and technologies, giving customers an edge and helping speed time to market. Over 1,200 semiconductor and electronic component manufacturer brands count on Mouser to help them introduce their products into the global marketplace. Mouser's customers can expect 100% certified, genuine products that are fully traceable from each manufacturer.Last quarter, Mouser launched almost16,500part numbers ready for shipment, with over 11,000 introduced in July alone.Some of the products introduced by Mouser from July through September include:. HARTING har-flexiconConnectors for Ethernet and SPE The har-flexicon connectors fromHARTINGare specifically designed and tested for Ethernet applications, ensuring robust and consistent connectivity. This connector series supports a variety of Ethernet standards and power options, including Single Pair Ether","market":"sh","thumbnail":"https://mma.prnewswire.com/media/2801249/new_product_insider_2400x1000.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2801249/new_product_insider_2400x1000.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/mouser-electronics-new-product-insider-over-16-000-new-parts-added-in-third-quarter-of-2025--302589773.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMU.AU","BK7508","SPE","BK7067"],"gpt_icon":0},{"id":"2568467974","title":"Imugene Says Drug Candidate Trial in Blood Cancer Patients Achieves 81% Overall Response Rate; Shares Rise 8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2568467974","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568467974?lang=en_us&edition=fundamental","pubTime":"2025-09-18 08:58","pubTimestamp":1758157126,"startTime":"0","endTime":"0","summary":"Imugene  said its Phase 1b clinical trial evaluating drug candidate azer-cel  in patients with blood cancer achieved an overall response rate  of 81%, up from an ORR of 79% in August, according to a Thursday filing with the Australian bourse.Thirteen out of sixteen patients showed a response to the treatment, the filing said.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","ORR","BK7067","ORR.AU","BK7095","IMU.AU"],"gpt_icon":0},{"id":"2562277166","title":"BRIEF-Imugene Posts FY Net Loss Attributable A$69 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2562277166","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562277166?lang=en_us&edition=fundamental","pubTime":"2025-08-26 09:34","pubTimestamp":1756172051,"startTime":"0","endTime":"0","summary":"BRIEF-Imugene Posts FY Net Loss Attributable A$69 MillionAug 26 (Reuters) - Imugene Ltd IMU.AX:FY NET LOSS ATTRIBUTABLE A$69 MILLIONFurther company coverage: IMU.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250826:nFWN3UH0NI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK7508","IMU.AU"],"gpt_icon":0},{"id":"2562276734","title":"Imugene Ltd -  FY Net Loss Attributable a$69 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2562276734","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562276734?lang=en_us&edition=fundamental","pubTime":"2025-08-26 07:22","pubTimestamp":1756164164,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250825:nFWN3UH0NI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","IMU.AU","BK7067"],"gpt_icon":0},{"id":"2558696573","title":"Imugene Ltd-Update - Proposed Issue of Securities - Imu","url":"https://stock-news.laohu8.com/highlight/detail?id=2558696573","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558696573?lang=en_us&edition=fundamental","pubTime":"2025-08-12 07:27","pubTimestamp":1754954839,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250811:nTUE3M5DBX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","BK7508","IMU.AU"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":35,"code":"91000000","status":"200"}]}}